Focus Partners Wealth Has $5.85 Million Stake in AstraZeneca PLC $AZN

Key Points

• Focus Partners Wealth increased its stake in AstraZeneca PLC by 15.3%, owning 79,640 shares valued at approximately $5.85 million at the end of the most recent quarter.
• Analysts have set a target price of $97.00 for AstraZeneca shares, with a consensus rating of "Moderate Buy" and an average price target of $86.00.
• AstraZeneca reported a revenue of $14.46 billion for the last quarter, exceeding analyst estimates, while also disclosing a semi-annual dividend of $0.505 per share.

Focus Partners Wealth boosted its holdings in shares of AstraZeneca PLC (NASDAQ:AZN - Free Report) by 15.3% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 79,640 shares of the company's stock after buying an additional 10,573 shares during the quarter. Focus Partners Wealth's holdings in AstraZeneca were worth $5,854,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Confluence Investment Management LLC acquired a new position in AstraZeneca during the first quarter worth $27,000. Larson Financial Group LLC increased its position in AstraZeneca by 297.9% during the first quarter. Larson Financial Group LLC now owns 386 shares of the company's stock worth $28,000 after buying an additional 289 shares during the last quarter. FNY Investment Advisers LLC acquired a new position in AstraZeneca during the first quarter worth $29,000. Costello Asset Management INC acquired a new position in AstraZeneca during the first quarter worth $29,000. Finally, Highline Wealth Partners LLC increased its position in AstraZeneca by 447.4% during the first quarter. Highline Wealth Partners LLC now owns 416 shares of the company's stock worth $31,000 after buying an additional 340 shares during the last quarter. 20.35% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Berenberg Bank set a $97.00 target price on shares of AstraZeneca in a research report on Wednesday, July 9th. Three research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $86.00.

AstraZeneca Stock Down 1.9%

Shares of AZN opened at $79.56 on Monday. The stock has a market cap of $246.74 billion, a price-to-earnings ratio of 29.91, a P/E/G ratio of 1.46 and a beta of 0.37. The company has a quick ratio of 0.67, a current ratio of 0.86 and a debt-to-equity ratio of 0.55. AstraZeneca PLC has a 12 month low of $61.24 and a 12 month high of $82.41. The company has a 50-day moving average price of $75.95 and a two-hundred day moving average price of $72.93.

AstraZeneca (NASDAQ:AZN - Get Free Report) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $1.09 earnings per share for the quarter, hitting the consensus estimate of $1.09. The company had revenue of $14.46 billion during the quarter, compared to analyst estimates of $14.08 billion. AstraZeneca had a net margin of 14.68% and a return on equity of 32.84%. The company's revenue was up 16.1% on a year-over-year basis. During the same quarter last year, the business posted $1.24 earnings per share. Equities analysts predict that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

AstraZeneca Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Monday, September 8th. Stockholders of record on Friday, August 8th were issued a dividend of $0.505 per share. The ex-dividend date of this dividend was Friday, August 8th. This represents a dividend yield of 200.0%. AstraZeneca's dividend payout ratio (DPR) is presently 37.97%.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.